In addition, treatment with nicardipine, an ABCG2 competitive inhibitor, sensitized CD133-positive glioma stem cells to mitoxantrone, whereas no synergistic effect was observed in CD133-negative tumor cells. This evidence concerns the gene ABCG2 and glioma.